Bulletin
Investor Alert

Sept. 23, 2022, 3:08 a.m. EDT

PFE Stock Price Predictions up as Pfizer/Biontech and Moderna Vaccines Get Nod From Eu's Ema Panel

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Pfizer Inc. (PFE)
  • X
    BioNTech SE ADR (BNTX)
  • X
    Moderna Inc. (MRNA)

or Cancel Already have a watchlist? Log In

Sep 23, 2022 (PressReach.com via COMTEX) -- PFE stock price predictions are up at 46.33+0.40 (+0.86%) as of 10:20 AM EDT by market open.

The CMA for the Comirnaty and Spikevax COVID-19 vaccines from Pfizer /zigman2/quotes/202877789/composite PFE -0.16% , BioNTech /zigman2/quotes/214419716/composite BNTX +1.31% , and Moderna /zigman2/quotes/205619834/composite MRNA -1.27% should be changed to normal marketing authorization, according to a committee of the European Medicines Agency (EMA).

The recently-approved adapted Comirnaty-Original/Omicron BA.1, Comirnaty-Original/Omicron BA.4/5, and Spikevax-bivalent Original/Omicron BA.1 vaccines are included in this recommendation, according to the EMA’s Committee for Medicinal Products for Human Use (CHMP). The government highlighted that although the authorizations are no longer required to be renewed yearly, the companies’ other duties are still in place.

The businesses were required to provide trial results that were still in progress and to offer further information about the vaccines’ pharmaceutical quality during the CMA. According to the CHMP, clinical trials and supplementary studies offered encouraging data on important factors, such as how well the vaccinations prevent severe COVID-19, and the firms also gave all the further data on the vaccines’ pharmaceutical quality that was required.

Pfizer Stock Up On Late-Stage Trials For New Vaccine

The specific obligations were no longer regarded as being essential to the benefit-risk of the products, according to CHMP, when the entirety of the efficacy and safety evidence from the widespread use of these vaccinations was taken into account, making room for conventional marketing approvals.

Analysts anticipate PFE’s sales for the fourth quarter of fiscal 2022 (ending in December 2022) to total $24.79 billion, up 4% from the same time last year. The $1.35 consensus EPS forecast for the same time period indicates a year-over-year rise of 25.3%. Additionally, during the previous four quarters, the company has consistently outperformed consensus EPS projections.

The company’s revenue and EPS are also anticipated to increase by 25.2% and 46.9% from the prior year to $101.74 billion and $6.49, respectively, for the current fiscal year 2022 (ending in December 2022).

Featured Image - Megapixl (C) Tiraspr

Please See Disclaimer

Visit PressReach.com To Get More Articles Like This

Author: Jowi Kwasu
Market Jar Media Inc.
info@marketjar.com
#170 - 422 Richards Street
Vancouver, BC, Canada
V6B 2Z4
1.800.340.9767

COMTEX_415103267/2810/2022-09-23T03:07:45

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 49.49
-0.08 -0.16%
Volume: 17.16M
Nov. 29, 2022 4:03p
P/E Ratio
9.53
Dividend Yield
3.23%
Market Cap
$278.25 billion
Rev. per Employee
$1.26M
loading...
/zigman2/quotes/214419716/composite
US : U.S.: Nasdaq
$ 163.61
+2.12 +1.31%
Volume: 935,658
Nov. 29, 2022 4:00p
P/E Ratio
3.65
Dividend Yield
0.00%
Market Cap
$39.19 billion
Rev. per Employee
$6.61M
loading...
/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 173.15
-2.23 -1.27%
Volume: 2.84M
Nov. 29, 2022 4:00p
P/E Ratio
6.26
Dividend Yield
N/A
Market Cap
$67.38 billion
Rev. per Employee
$7.86M
loading...

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.